{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:35:10Z","timestamp":1791920110867,"version":"4.3.4"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["metabolismjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.metabol.2023.155657","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T12:15:37Z","timestamp":1688645737000},"page":"155657","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":120,"special_numbering":"C","title":["SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis"],"prefix":"10.1016","volume":"146","author":[{"given":"Yunfeng","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minxuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanrong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2023.155657_bb0005","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2023.155657_bb0010","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2023.155657_bb0015","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA."},{"key":"10.1016\/j.metabol.2023.155657_bb0020","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/hep.27332","article-title":"Hepatic inflammation and fibrosis: functional links and key pathways","volume":"61","author":"Seki","year":"2015","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2023.155657_bb0025","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2023.155657_bb0030","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1053\/j.gastro.2008.03.003","article-title":"Mechanisms of hepatic fibrogenesis","volume":"134","author":"Friedman","year":"2008","journal-title":"Gastroenterology."},{"key":"10.1016\/j.metabol.2023.155657_bb0035","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrg2843","article-title":"The widespread regulation of microRNA biogenesis, function and decay","volume":"11","author":"Krol","year":"2010","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.metabol.2023.155657_bb0040","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","article-title":"MicroRNAs: target recognition and regulatory functions","volume":"136","author":"Bartel","year":"2009","journal-title":"Cell."},{"key":"10.1016\/j.metabol.2023.155657_bb0045","article-title":"miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice","volume":"8","author":"Rodrigues","year":"2017","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.metabol.2023.155657_bb0050","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.3892\/ol.2017.5623","article-title":"MicroRNA-29a\/b\/c targets iNOS and is involved in protective remote ischemic preconditioning in an ischemia-reperfusion rat model of non-alcoholic fatty liver disease","volume":"13","author":"Duan","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.metabol.2023.155657_bb0055","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/ddr.22020","article-title":"Therapeutic role of Artemether in the prevention of hepatic steatosis through miR-34a-5p\/PPARalpha pathway","volume":"84","author":"Chen","year":"2023","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.metabol.2023.155657_bb0060","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s10020-019-0085-2","article-title":"miR-122 promotes hepatic lipogenesis via inhibiting the LKB1\/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease","volume":"25","author":"Long","year":"2019","journal-title":"Mol Med"},{"key":"10.1016\/j.metabol.2023.155657_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119071","article-title":"miR-125b promotes the NF-kappaB-mediated inflammatory response in NAFLD via directly targeting TNFAIP3","volume":"270","author":"Zhang","year":"2021","journal-title":"Life Sci"},{"key":"10.1016\/j.metabol.2023.155657_bb0070","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41374-021-00626-1","article-title":"Steatosis, inflammasome upregulation, and fibrosis are attenuated in miR-155 deficient mice in a high fat-cholesterol-sugar diet-induced model of NASH","volume":"101","author":"Bala","year":"2021","journal-title":"Lab Investig"},{"key":"10.1016\/j.metabol.2023.155657_bb0075","doi-asserted-by":"crossref","first-page":"6884","DOI":"10.3390\/ijms21186884","article-title":"miR-29a modulates GSK3beta\/SIRT1-linked mitochondrial proteostatic stress to ameliorate mouse non-alcoholic steatohepatitis","volume":"21","author":"Yang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2023.155657_bb0080","doi-asserted-by":"crossref","first-page":"8140","DOI":"10.3748\/wjg.v23.i46.8140","article-title":"miR-192-5p regulates lipid synthesis in non-alcoholic fatty liver disease through SCD-1","volume":"23","author":"Liu","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.metabol.2023.155657_bb0085","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2023.155657_bb0090","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation."},{"key":"10.1016\/j.metabol.2023.155657_bb0095","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrendo.2011.243","article-title":"SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects","volume":"8","author":"Ferrannini","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.metabol.2023.155657_bb0100","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.2337\/dc21-2049","article-title":"Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-label, active-controlled trial","volume":"45","author":"Takeshita","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2023.155657_bb0105","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2023.155657_bb0110","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2023.155657_bb0115","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2023.155657_bb0120","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s13300-021-01011-3","article-title":"Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial","volume":"12","author":"Chehrehgosha","year":"2021","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.metabol.2023.155657_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2020.100086","article-title":"Protocol for primary mouse hepatocyte isolation","volume":"1","author":"Charni-Natan","year":"2020","journal-title":"STAR Protoc"},{"key":"10.1016\/j.metabol.2023.155657_bb0130","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-2815-6_1","article-title":"Isolation of non-parenchymal cells from the mouse liver","volume":"1325","author":"Mohar","year":"2015","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.metabol.2023.155657_bb0135","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bcp.2018.03.013","article-title":"Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells","volume":"152","author":"Xu","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.metabol.2023.155657_bb0140","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1074\/mcp.M113.035600","article-title":"Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics","volume":"13","author":"Fagerberg","year":"2014","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.metabol.2023.155657_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.780617","article-title":"Analysis of N6-methyladenosine methylation modification in fructose-induced non-alcoholic fatty liver disease","volume":"12","author":"Luo","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.metabol.2023.155657_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.101331","article-title":"A retinoic acid receptor beta2 agonist attenuates transcriptome and metabolome changes underlying nonalcohol-associated fatty liver disease","volume":"297","author":"Tang","year":"2021","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2023.155657_bb0155","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.mam.2018.09.002","article-title":"Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues","volume":"65","author":"Parola","year":"2019","journal-title":"Mol Asp Med"},{"key":"10.1016\/j.metabol.2023.155657_bb0160","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.tig.2022.02.006","article-title":"Emerging concepts of miRNA therapeutics: from cells to clinic","volume":"38","author":"Diener","year":"2022","journal-title":"Trends Genet"},{"key":"10.1016\/j.metabol.2023.155657_bb0165","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.cmet.2019.07.011","article-title":"Extracellular miRNAs: from biomarkers to mediators of physiology and disease","volume":"30","author":"Mori","year":"2019","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2023.155657_bb0170","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.addr.2018.01.009","article-title":"MicroRNAs in the pathogenesis and treatment of progressive liver injury in NAFLD and liver fibrosis","volume":"129","author":"Su","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.metabol.2023.155657_bb0175","doi-asserted-by":"crossref","first-page":"16137","DOI":"10.1073\/pnas.1205951109","article-title":"Aberrantly elevated microRNA-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor beta-r","volume":"109","author":"Fu","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.metabol.2023.155657_bb0180","doi-asserted-by":"crossref","first-page":"7466","DOI":"10.1038\/ncomms8466","article-title":"A metabolic stress-inducible miR-34a-HNF4alpha pathway regulates lipid and lipoprotein metabolism","volume":"6","author":"Xu","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.metabol.2023.155657_bb0185","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S2468-1253(20)30252-1","article-title":"A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study","volume":"5","author":"Harrison","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2023.155657_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101244","article-title":"Hepatocyte miR-34a is a key regulator in the development and progression of non-alcoholic fatty liver disease","volume":"51","author":"Xu","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.metabol.2023.155657_bb0195","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1111\/febs.13665","article-title":"TGF-beta signalling and liver disease","volume":"283","author":"Fabregat","year":"2016","journal-title":"FEBS J"},{"key":"10.1016\/j.metabol.2023.155657_bb0200","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41575-021-00571-w","article-title":"Hippo signalling in the liver: role in development, regeneration and disease","volume":"19","author":"Russell","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2023.155657_bb0205","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrgastro.2010.213","article-title":"NF-kappaB in the liver--linking injury, fibrosis and hepatocellular carcinoma","volume":"8","author":"Luedde","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2023.155657_bb0210","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1016\/j.biochi.2013.09.003","article-title":"Wnt signaling in liver fibrosis: progress, challenges and potential directions","volume":"95","author":"Miao","year":"2013","journal-title":"Biochimie."},{"key":"10.1016\/j.metabol.2023.155657_bb0215","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0168-8278(99)80010-5","article-title":"The role of TGFbeta1 in initiating hepatic stellate cell activation in vivo","volume":"30","author":"Hellerbrand","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2023.155657_bb0220","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3389\/fonc.2018.00357","article-title":"Transforming growth factor-beta-induced cell plasticity in liver fibrosis and hepatocarcinogenesis","volume":"8","author":"Fabregat","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.metabol.2023.155657_bb0225","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/cphy.c120035","article-title":"Hepatic stellate cells and liver fibrosis","volume":"3","author":"Puche","year":"2013","journal-title":"Compr Physiol"},{"key":"10.1016\/j.metabol.2023.155657_bb0230","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1006\/dbio.1999.9240","article-title":"A mouse cerberus\/Dan-related gene family","volume":"209","author":"Pearce","year":"1999","journal-title":"Dev Biol"},{"key":"10.1016\/j.metabol.2023.155657_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103969","article-title":"GREM2 is associated with human central obesity and inhibits visceral preadipocyte browning","volume":"78","author":"Liu","year":"2022","journal-title":"EBioMedicine."},{"key":"10.1016\/j.metabol.2023.155657_bb0240","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S2468-1253(21)00261-2","article-title":"Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review","volume":"7","author":"Mantovani","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2023.155657_bb0245","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia."},{"key":"10.1016\/j.metabol.2023.155657_bb0250","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/ijms19010137","article-title":"The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents renal and liver disease in Western diet induced obesity mice","volume":"19","author":"Wang","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2023.155657_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2019.110539","article-title":"Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress","volume":"498","author":"Petito-da-Silva","year":"2019","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.metabol.2023.155657_bb0260","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1042\/CS20190863","article-title":"Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats","volume":"133","author":"Swe","year":"2019","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.metabol.2023.155657_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106730","article-title":"Potential anti-inflammatory effect of dapagliflozin in HCHF diet- induced fatty liver degeneration through inhibition of TNF-alpha, IL-1beta, and IL-18 in rat liver","volume":"86","author":"ElMahdy","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.metabol.2023.155657_bb0270","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejphar.2018.03.043","article-title":"Canagliflozin protects against non-alcoholic steatohepatitis in type-2 diabetic rats through zinc alpha-2 glycoprotein up-regulation","volume":"828","author":"Kabil","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.metabol.2023.155657_bb0275","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13098-016-0169-x","article-title":"Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes","volume":"8","author":"Jojima","year":"2016","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.metabol.2023.155657_bb0280","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00535-016-1200-6","article-title":"Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats","volume":"51","author":"Nishimura","year":"2016","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.metabol.2023.155657_bb0285","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejphar.2015.02.009","article-title":"Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats","volume":"754","author":"Hayashizaki-Someya","year":"2015","journal-title":"Eur J Pharmacol"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049523002615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049523002615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T19:37:24Z","timestamp":1736365044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049523002615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":57,"alternative-id":["S0026049523002615"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2023.155657","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2023.155657","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"155657"}}